Therapeutics and Clinical Risk Management, 2015 Katsuhiko Shimizu, Riki Okita, Shinsuke Saisho, Takuro Yukawa, Ai Maeda, Yuji Nojima, Masao Nakata Department of General Thoracic Surgery, Kawasaki Medical School, Kurashiki, Japan Background: Adjuvant chemotherapy after the complete resection of non ...
Shimizu K +6 more
doaj +1 more source
Update on Adjuvant Chemotherapy for Early Breast Cancer
Breast Cancer: Basic and Clinical Research, 2014 Breast cancer is the second most common cancer in women worldwide. Although most women are diagnosed with early breast cancer, a substantial number recur due to persistent micro-metastatic disease. Systemic adjuvant chemotherapy improves outcomes and has
Murtuza M. Rampurwala +2 more
doaj +2 more sources
Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy : results from the BIG 02-98 phase III trial [PDF]
, 2012 Introduction: Pre-clinical data suggest p53-dependent anthracycline-induced apoptosis and p53-independent taxane activity. However, dedicated clinical research has not defined a predictive role for TP53 gene mutations. The aim of the current study was to
Viale, Giuseppe +16 more
core +5 more sources
Diabetes alone should not be a reason for withholding adjuvant chemotherapy for stage III colon cancer [PDF]
, 2011 Background: With increasing prevalence of diabetes mellitus and colon cancer, the number of patients suffering from both diseases is growing, and physicians are being faced with complicated treatment decisions.
Wouter M. W. Dercksen +11 more
core +1 more source
Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients : analysis of >4,500 patients from four German randomized breast cancer trials [PDF]
, 2008 Introduction: Despite the fact that people older than 65 years of age have the highest incidence of developing breast cancer, these patients are excluded from clinical trials in most cases.
Kümmel, Sherko +22 more
core +2 more sources
The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation [PDF]
, 2006 Objectives: To assess the clinical and cost-effectiveness of oxaliplatin in combination with 5-fluorouracil/ leucovorin (5-FU/LV), and capecitabine monotherapy (within their licensed indications), as adjuvant therapies in the treatment of ...
Tappenden, P. +11 more
core +1 more source
Is adjuvant chemotherapy justified in rectal cancer patients after radiochemotherapy and radical resection? [PDF]
, 2018 Recommendations for the application of post-operative adjuvant chemotherapy in patients who received preoperative radio-chemotherapy are not consistent.
Bujko, Krzysztof
core +1 more source
Variations in the body mass index in Brazilian women undergoing adjuvant chemotherapy for breast cancer [PDF]
Revista Brasileira de Ginecologia e Obstetrícia, 2014 PURPOSE:To evaluate variations in the body mass index in patients undergoing adjuvant chemotherapy for breast cancer, and to associate these changes with patient's age and adjuvant chemotherapy regimen.METHODS:We performed a retrospective cohort study in
Marcos Desídérío Ricci +7 more
doaj +2 more sources
Node-positive breast cancer: Which are the best chemotherapy regimens? [PDF]
, 2008 Breast cancer-associated mortality has been significantly reduced since the 1990s, mainly because of early diagnosis and systemic therapeutic interventions.
Bauerfeind, Ingo +6 more
core +1 more source
BMC Cancer, 2018 Background There is no consensus regarding the optimal time to initiate adjuvant chemotherapy after surgery for stage III colon cancer, and the relevant postoperative complications that cause delays in adjuvant chemotherapy are unknown.
Peng Gao +7 more
doaj +1 more source